http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 05 Mar 2026 06:51:39 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Amylyx+Pharmaceuticals+inc.+%28AMLX%29+PT+Raised+to+%2434+at+H.C.+Wainwright/26114776.html (Updated - March 5, 2026 6:51 AM EST) <p>H.C. Wainwright analyst Andrew Fein raised the price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) to $34.00 (from $28.00) while maintaining a Buy rating.</p><p>The analyst commented: "Our recent engagement with institutional investors and KOLs has shifted the focus toward four technical debates surrounding the Phase 3 LUCIDITY trial: (1) on the question of Phase 2b showing potential inter-patient variability, we note that based on the population PK model, the 90 mg avexitide exceeded IC50 for 24 hours and maintained IC90 from morning to midnight (the PK of avexitide in plasma was evaluated in http://www.streetinsider.com/Analyst+PT+Change/Amylyx+Pharmaceuticals+inc.+%28AMLX%29+PT+Raised+to+%2434+at+H.C.+Wainwright/26114776.html Thu, 05 Mar 2026 06:51:39 -0500 AMLX http://www.streetinsider.com/Analyst+Comments/Amylyx+Pharmaceuticals+inc.+%28AMLX%29+PT+Raised+to+%2434+at+H.C.+Wainwright/26114776.html (Updated - March 5, 2026 6:51 AM EST) <p>H.C. Wainwright analyst Andrew Fein raised the price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) to $34.00 (from $28.00) while maintaining a Buy rating.</p><p>The analyst commented: "Our recent engagement with institutional investors and KOLs has shifted the focus toward four technical debates surrounding the Phase 3 LUCIDITY trial: (1) on the question of Phase 2b showing potential inter-patient variability, we note that based on the population PK model, the 90 mg avexitide exceeded IC50 for 24 hours and maintained IC90 from morning to midnight (the PK of avexitide in plasma was evaluated in http://www.streetinsider.com/Analyst+Comments/Amylyx+Pharmaceuticals+inc.+%28AMLX%29+PT+Raised+to+%2434+at+H.C.+Wainwright/26114776.html Thu, 05 Mar 2026 06:51:39 -0500 AMLX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Mazzariello+Gina/26110767.html si-local-file:///var/storage/secattach/20260304/26110767.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Mazzariello+Gina/26110767.html Wed, 04 Mar 2026 16:00:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Mazzariello+Gina/26110767.html si-local-file:///var/storage/secattach/20260304/26110767.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Mazzariello+Gina/26110767.html Wed, 04 Mar 2026 16:00:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+FRATES+JAMES+M/26110769.html si-local-file:///var/storage/secattach/20260304/26110769.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+FRATES+JAMES+M/26110769.html Wed, 04 Mar 2026 16:00:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+FRATES+JAMES+M/26110769.html si-local-file:///var/storage/secattach/20260304/26110769.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+FRATES+JAMES+M/26110769.html Wed, 04 Mar 2026 16:00:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Bedrosian+Camille+L/26110770.html si-local-file:///var/storage/secattach/20260304/26110770.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Bedrosian+Camille+L/26110770.html Wed, 04 Mar 2026 16:00:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Bedrosian+Camille+L/26110770.html si-local-file:///var/storage/secattach/20260304/26110770.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Bedrosian+Camille+L/26110770.html Wed, 04 Mar 2026 16:00:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Cohen+Joshua+B/26110771.html si-local-file:///var/storage/secattach/20260304/26110771.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Cohen+Joshua+B/26110771.html Wed, 04 Mar 2026 16:00:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Cohen+Joshua+B/26110771.html si-local-file:///var/storage/secattach/20260304/26110771.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Cohen+Joshua+B/26110771.html Wed, 04 Mar 2026 16:00:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Klee+Justin+B./26110777.html si-local-file:///var/storage/secattach/20260304/26110777.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Klee+Justin+B./26110777.html Wed, 04 Mar 2026 16:00:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Klee+Justin+B./26110777.html si-local-file:///var/storage/secattach/20260304/26110777.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+02++Filed+by%3A+Klee+Justin+B./26110777.html Wed, 04 Mar 2026 16:00:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Amylyx+Pharmaceuticals%2C++++++++++++++/26101116.html si-local-file:///var/storage/secattach/20260303/26101116.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Amylyx+Pharmaceuticals%2C++++++++++++++/26101116.html Tue, 03 Mar 2026 16:04:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Amylyx+Pharmaceuticals%2C++++++++++++++/26101116.html si-local-file:///var/storage/secattach/20260303/26101116.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Amylyx+Pharmaceuticals%2C++++++++++++++/26101116.html Tue, 03 Mar 2026 16:04:00 -0500 AMLX O.30945667 http://www.streetinsider.com/Equity+Offerings/Amylyx+Pharmaceuticals+%28AMLX%29+files+mixed+shelf/26096947.html <p>Amylyx Pharmaceuticals (NASDAQ: AMLX) has filed mixed shelf of:</p><p>COMMON STOCK</p><p>PREFERRED STOCK</p><p>DEBT SECURITIES</p><p>WARRANTS</p><p>UNITS</p> http://www.streetinsider.com/Equity+Offerings/Amylyx+Pharmaceuticals+%28AMLX%29+files+mixed+shelf/26096947.html Tue, 03 Mar 2026 08:05:45 -0500 AMLX http://www.streetinsider.com/Corporate+News/Amylyx+Pharmaceuticals+%28AMLX%29+files+mixed+shelf/26096947.html <p>Amylyx Pharmaceuticals (NASDAQ: AMLX) has filed mixed shelf of:</p><p>COMMON STOCK</p><p>PREFERRED STOCK</p><p>DEBT SECURITIES</p><p>WARRANTS</p><p>UNITS</p> http://www.streetinsider.com/Corporate+News/Amylyx+Pharmaceuticals+%28AMLX%29+files+mixed+shelf/26096947.html Tue, 03 Mar 2026 08:05:45 -0500 AMLX http://www.streetinsider.com/SEC+Filings/Form++S-3ASR+++++Amylyx+Pharmaceuticals%2C++++++++++++++/26096896.html si-local-file:///var/storage/secattach/20260303/26096896.html http://www.streetinsider.com/SEC+Filings/Form++S-3ASR+++++Amylyx+Pharmaceuticals%2C++++++++++++++/26096896.html Tue, 03 Mar 2026 08:01:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++S-3ASR+++++Amylyx+Pharmaceuticals%2C++++++++++++++/26096896.html si-local-file:///var/storage/secattach/20260303/26096896.html http://www.streetinsider.com/SEC+Filings/Form++S-3ASR+++++Amylyx+Pharmaceuticals%2C++++++++++++++/26096896.html Tue, 03 Mar 2026 08:01:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Amylyx+Pharmaceuticals%2C+++For%3A+Dec+31/26096397.html si-local-file:///var/storage/secattach/20260303/26096397.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Amylyx+Pharmaceuticals%2C+++For%3A+Dec+31/26096397.html Tue, 03 Mar 2026 07:11:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Amylyx+Pharmaceuticals%2C+++For%3A+Dec+31/26096397.html si-local-file:///var/storage/secattach/20260303/26096397.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Amylyx+Pharmaceuticals%2C+++For%3A+Dec+31/26096397.html Tue, 03 Mar 2026 07:11:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+03/26096356.html si-local-file:///var/storage/secattach/20260303/26096356.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+03/26096356.html Tue, 03 Mar 2026 07:03:00 -0500 AMLX O.30945667 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+03/26096356.html si-local-file:///var/storage/secattach/20260303/26096356.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Amylyx+Pharmaceuticals%2C+++For%3A+Mar+03/26096356.html Tue, 03 Mar 2026 07:03:00 -0500 AMLX O.30945667 http://www.streetinsider.com/Earnings/Amylyx+Pharmaceuticals%2C+Inc.+%28AMLX%29+Tops+Q4+EPS+by+4c/26096309.html <p>Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q4 EPS of ($0.30), $0.04 better than the analyst estimate of ($0.34).</p><p>For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) <a href="http://www.streetinsider.com/ec_earnings.php?q=AMLX">click here</a>.</p> http://www.streetinsider.com/Earnings/Amylyx+Pharmaceuticals%2C+Inc.+%28AMLX%29+Tops+Q4+EPS+by+4c/26096309.html Tue, 03 Mar 2026 07:00:49 -0500 AMLX http://www.streetinsider.com/Press+Releases/Amylyx+Pharmaceuticals+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26096278.html <ul class="bwlistdisc"> <li> <i>Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026</i> </li> <li> <i>Cash runway expected to fund operations through potential avexitide commercialization and into 2028</i> </li> <li> <i>Management to host conference call and webcast today at 8:00 a.m. Eastern Time</i> </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.amylyx.com%2F&amp;esheet=54436857&amp;newsitemid=20260303771323&amp;lan=en-US&amp;anchor=Amylyx+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=90ba8b3f2e99c00f942a2c9e60578cde" shape="rect">Amylyx Pharmaceuticals, Inc.</a> (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial and business results for the fourth quarter and full year ended December 31, 2025. </p><p> “2025 was a year of meaningful advancement http://www.streetinsider.com/Press+Releases/Amylyx+Pharmaceuticals+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26096278.html Tue, 03 Mar 2026 07:00:00 -0500 A.06822034 AMLX O.20026344 O.30945667 http://www.streetinsider.com/Press+Releases/Amylyx+Pharmaceuticals+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26096278.html <ul class="bwlistdisc"> <li> <i>Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026</i> </li> <li> <i>Cash runway expected to fund operations through potential avexitide commercialization and into 2028</i> </li> <li> <i>Management to host conference call and webcast today at 8:00 a.m. Eastern Time</i> </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.amylyx.com%2F&amp;esheet=54436857&amp;newsitemid=20260303771323&amp;lan=en-US&amp;anchor=Amylyx+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=90ba8b3f2e99c00f942a2c9e60578cde" shape="rect">Amylyx Pharmaceuticals, Inc.</a> (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial and business results for the fourth quarter and full year ended December 31, 2025. </p><p> “2025 was a year of meaningful advancement http://www.streetinsider.com/Press+Releases/Amylyx+Pharmaceuticals+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26096278.html Tue, 03 Mar 2026 07:00:00 -0500 A.06822034 AMLX O.20026344 O.30945667